EMVision Medical Devices (ASX: EMV) has reported significant EMVision emu Clinical Trial Progress across its pivotal validation study, with seven world-class stroke hospitals now actively recruiting participants. The company’s emu point-of-care brain scanner is positioned to address critical diagnostic gaps in acute stroke care through a multi-site validation programme targeting FDA De Novo clearance.
Seven world-class stroke hospitals now recruiting for emu pivotal trial
EMVision’s pivotal validation trial has reached full operational capacity across six flagship locations encompassing seven hospitals in total. The trial spans four US sites and two Australian centres, providing access to diverse, high-volume stroke populations critical for regulatory validation.
Active recruiting locations include:
- Mayo Clinic (Florida, US)
- Mt Sinai (New York, US) including newly activated Mt Sinai West network hospital
- Memorial Hermann (Texas, US) with Memorial Hermann Memorial City expected to commence next month
- UCLA (California, US)
- The Royal Melbourne Hospital (Victoria, Australia)
- Liverpool Hospital (New South Wales, Australia)
The recent activation of Mt Sinai West in Manhattan’s West Midtown area represents a strategic expansion of the trial’s recruitment capacity. Located within a high-volume healthcare network, this additional site became operational in late December. Memorial Hermann Memorial City in Houston’s west is finalising activation procedures and is due to commence enrolling participants next month.
The trial aims to enrol 300 suspected stroke participants for primary analysis, with the primary objective of demonstrating haemorrhage detection sensitivity and specificity greater than 80%. This threshold is critical for supporting regulatory submission to the US Food and Drug Administration.
Access to multiple world-class Comprehensive Stroke Centres provides EMVision with recruitment advantages that could accelerate the trial timeline whilst ensuring data quality across demographically diverse patient populations. These flagship institutions validate the emu technology’s credibility within the acute stroke diagnosis field.
When big ASX news breaks, our subscribers know first
Recruitment momentum building toward first half CY2026 completion
EMVision maintains its target of completing recruitment in the first half of CY2026, supported by week-on-week acceleration in enrolment rates. In acute stroke device trials, recruitment typically follows an exponential pattern rather than linear progression. This trajectory is driven by initial operational ramp-up, followed by accelerated enrolment as sites mature and clinical workflows optimise.
The company’s experience with its previous EMView clinical trial supports confidence in this recruitment pattern. As participating hospitals refine their screening processes and integrate the emu scanner into emergency department protocols, the pace of patient identification and enrolment is expected to increase substantially.
Training verification driving software enhancement
EMVision’s deliberate approach to trial preparation has included rigorous training verification at each participating site. Several patients were recruited and scanned during this verification phase, with these scans excluded from the primary analysis cohort to maintain data integrity.
Operational learnings from the training verification process have been systematically incorporated into trial execution protocols. Feedback from clinical users and evaluation of verification data has enabled development of a new software feature that provides real-time scan quality feedback at the point of acquisition. This enhancement is currently undergoing in-house testing ahead of integration into emu devices.
This continuous improvement cycle strengthens the commercial product ahead of regulatory clearance whilst minimising operational variability during the pivotal trial. The disciplined execution reduces risk of data quality issues that could delay regulatory timelines.
CEO Commentary
“We have taken a deliberate and disciplined approach to preparing the emu Pivotal (Validation) Trial, with a strong focus on site readiness, training verification, and data quality. With all flagship locations now actively recruiting, additional network sites coming online, and enrolment acceleration taking place, we expect the pace of enrolling to continue to increase as the Trial continues. We are pleased with the progress to date, the engagement of our clinical collaborators and look forward to achieving our recruitment and trial objectives,” said Scott Kirkland, CEO and Managing Director of EMVision.
Understanding the path to FDA De Novo clearance
EMVision’s emu brain scanner is pursuing FDA clearance through the De Novo pathway, a regulatory route designed specifically for novel medical devices with no existing predicate device. This classification applies to first-of-kind technologies that present low to moderate risk but cannot be cleared through the traditional 510(k) pathway due to lack of comparable devices.
The De Novo pathway requires submission of clinical data demonstrating safety and effectiveness for the intended use. For emu, this means validating its ability to detect intracranial haemorrhage with clinically meaningful sensitivity and specificity in suspected stroke patients.
Following completion of the pivotal trial recruitment and data analysis, EMVision will compile a regulatory submission file for FDA review. The review process typically requires 9-12 months from submission to decision. In parallel, the company is progressing towards Therapeutic Goods Administration (TGA) approval for Australian market access, targeted for 2027.
FDA De Novo clearance would open access to the US stroke diagnostics market whilst establishing emu as the regulatory benchmark for future portable brain imaging competitors. As the first device in its class to achieve clearance, emu would set the predicate standard that subsequent technologies would need to match or exceed.
| Milestone | Status | Expected Timing | Significance |
|---|---|---|---|
| Pivotal Trial Recruitment | Underway | 1H CY2026 completion | Generates primary analysis data for regulatory submission |
| Regulatory File Submission | Pending | Following recruitment completion | Initiates FDA De Novo review process |
| FDA De Novo Decision | Pending | 9-12 months post-submission | US market access and commercialisation |
| TGA Approval | Pending | 2027 | Australian market access |
Parallel clinical programmes expand emu evidence base
Continuous Innovation Study fuels algorithm development
EMVision’s Continuous Innovation Study operates in parallel to the pivotal trial at separate Australian clinical sites. The study is enrolling up to 300 suspected stroke and traumatic brain injury patients at Comprehensive Stroke Centres and Level 1 Trauma Centres.
Current participating sites include Princess Alexandra Hospital and John Hunter Hospital, with Box Hill Hospital at advanced stages of activation. The study went live in Q3 CY2025 and has been progressing since that time.
The critical function of this study is to provide additional training data for ongoing algorithm refinement, feature development, and indication expansion beyond haemorrhage detection. Because this data is collected independently from the pivotal trial, it enables continuous improvement of the emu platform without compromising the integrity of the regulatory validation study.
Ongoing incorporation of real-world data from diverse patient populations enables EMVision to refine its algorithms over time, improving diagnostic accuracy and reliability across varied clinical environments. This positions the commercial product for enhanced clinical performance and competitive differentiation at launch.
Grant-funded Regional Benefits Study targets real-world adoption evidence
EMVision was awarded a $3 million non-dilutive grant under the Australian Government’s Cooperative Research Centres Projects (CRC-P) Round 17 programme to support a regional clinical benefits study. This funding preserves shareholder value whilst enabling critical real-world evidence generation.
The study will evaluate the real-world benefits of deploying the emu brain scanner integrated with telehealth networks in regional hospitals across South Australia. These environments typically have limited access to advanced neuroimaging and specialist stroke clinicians, making point-of-care diagnostic capability particularly valuable.
Project partners include the Australian Stroke Alliance, Titan Pre-hospital Innovation, and South Australia’s Rural Support Service. With funding and collaboration agreements now executed, the project team is establishing clinical workflows and protocols ahead of ethics submission and site activation. The study is expected to launch in the second half of CY2026.
This represents the first study designed to demonstrate real-world clinical benefit of the emu scanner in routine practice. The resulting data will form part of a comprehensive clinical and economic evidence dossier critical for driving adoption and supporting reimbursement negotiations with healthcare systems and insurers.
Summary of EMVision’s three clinical programmes:
- Pivotal (Validation) Trial: 300 participants across 6 flagship sites (7 hospitals total) targeting FDA De Novo clearance through demonstration of >80% haemorrhage detection sensitivity and specificity
- Continuous Innovation Study: Up to 300 stroke and traumatic brain injury patients across Australian sites enabling ongoing algorithm refinement and feature development without compromising pivotal trial integrity
- Regional Benefits Study: Grant-funded real-world evidence generation in regional South Australian hospitals demonstrating clinical utility and economic value in resource-limited settings
The next major ASX story will hit our subscribers first
What this means for EMVision’s investment thesis
EMVision emu Clinical Trial Progress positions the company for multiple value inflection points through 2026-2027. Completion of pivotal trial recruitment in the first half of CY2026 would enable regulatory file submission in mid-2026, with potential FDA De Novo clearance by mid-to-late 2027 based on typical review timelines.
The emu brain scanner addresses an unmet clinical need in point-of-care stroke diagnosis. Current standard of care requires transport to CT or MRI imaging facilities, introducing delays that can compromise treatment outcomes in time-sensitive conditions like intracranial haemorrhage. A portable, bedside diagnostic device that achieves clinically meaningful sensitivity and specificity could enable faster triage and treatment decisions.
The trial’s sequential validation design allows EMVision to pursue additional diagnostic features, such as ischaemia detection, without requiring supplementary full validation trials. This design efficiency accelerates the pathway to expanded indications whilst managing clinical development costs.
Management execution against stated timelines demonstrates operational discipline. The deliberate approach to site activation, training verification, and data quality protocols reduces regulatory risk whilst building a stronger commercial product through continuous software enhancement based on real-world clinical feedback.
The parallel clinical programmes create a growing evidence base that extends beyond regulatory requirements. Real-world benefit data from the Regional Benefits Study and algorithm improvements from the Continuous Innovation Study support commercialisation momentum by addressing adoption barriers related to clinical utility and economic value.
Successful recruitment completion in the first half of CY2026 would de-risk the regulatory pathway and validate the company’s clinical development strategy. With seven hospitals now actively recruiting and recruitment rates accelerating week-on-week, EMVision (ASX: EMV) is progressing toward this critical milestone.
Want more Biotech breakthroughs delivered to your inbox?
EMVision’s progress through FDA-critical validation milestones represents the type of regulatory catalyst that moves biotech stocks. For investors tracking ASX Biotech and Healthcare opportunities, missing the next trial result or regulatory announcement can mean missing significant price movements.
The Big News Blast from StockWire X delivers FREE breaking news and in-depth analysis across non-resource ASX sectors including Biotech, Healthcare, Technology, and Finance. Trusted by over 20,000+ active subscribers, these alerts cut through market noise to deliver actionable intelligence on companies progressing toward commercial milestones. Click the “Free Alerts” button at the top of this page to ensure the next pivotal development reaches your inbox before the market reacts.